XP Diagnostics

XP Diagnostics is a German diagnostics subsidiary focused on rapid point-of-care infectious disease and oral health testing. Public disclosures describe XP Diagnostics GmbH as a wholly owned German subsidiary of XPhyto Therapeutics, now BioNxt Solutions, and position it around commercialization of Covid-ID Lab and integration of 3a-diagnostics' oral biosensor technologies. Its activities have included a CE-marked rapid RT-PCR COVID-19 test platform and development of proprietary saliva- or oral-based biosensor screening tests for bacterial and viral infections. The company appears to function as a diagnostics operating unit within BioNxt's broader German organization rather than as an independent public biotech with its own standalone financing history. Available information suggests a focus on European commercialization, business development, sales support, and diagnostic product development.